Edition:
United States

Arcturus Therapeutics Ltd (ARCT.OQ)

ARCT.OQ on NASDAQ Stock Exchange Global Market

9.40USD
22 Jun 2018
Change (% chg)

-- (--)
Prev Close
$9.40
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
10,078
52-wk High
$15.19
52-wk Low
$4.84

Chart for

About

Arcturus Therapeutics Ltd, formerly Alcobra Ltd, is an Israel-based preclinical-stage biopharmaceutical company primarily focused on the discovery, development and commercialization of ribonucleic acid (RNA) medicines using lipid-mediated nanoparticle delivery system (LUNAR) and Unlocked Nucleomonomer Agent (UNA) Oligomer... (more)

Overall

Beta: 1.74
Market Cap(Mil.): $100.94
Shares Outstanding(Mil.): 10.74
Dividend: --
Yield (%): --

Financials

  ARCT.OQ Industry Sector
P/E (TTM): -- 248.83 34.14
EPS (TTM): -4.60 -- --
ROI: -47.41 -5.25 13.10
ROE: -61.64 -6.83 15.09

BRIEF-Amir Efrati Reports 5.3 Percent Stake In Arcturus Therapeutics

* AMIR EFRATI - ON APRIL 27, SENT LETTER TO ISRAELI COURT SHOWING OPPOSITION TO TRANSACTION THEY BELIEVE ARCTURUS THERAPEUTICS BOARD HAS BEEN PURSUING

Apr 30 2018

BRIEF-Joseph Payne Says "Rejects" Arcturus Therapeutics' Board Of Directors' Latest Lawsuit Against Payne

* JOSEPH PAYNE SAYS "REJECTS" ARCTURUS THERAPEUTICS' BOARD OF DIRECTORS' LATEST LAWSUIT AGAINST PAYNE

Apr 23 2018

BRIEF-Arcturus Therapeutics Files Lawsuit Against Former CEO Joseph Payne And His Associates

* ARCTURUS THERAPEUTICS FILES LAWSUIT AGAINST JOSEPH E. PAYNE AND HIS ASSOCIATES FOR VIOLATIONS OF FEDERAL SECURITIES LAWS

Apr 20 2018

BRIEF-Joseph Payne Sent Letter To Arcturus Board To Restate Prior Demand To Convene EGM

* JOSEPH E. PAYNE -ON APRIL 18, SENT LETTER TO ARCTURUS THERAPEUTICS LTD. BOARD TO RESTATE HIS PRIOR DEMAND TO CONVENE EGM OF SHAREHOLDERS - SEC FILING Source text: (https://bit.ly/2F05p2z) Further company coverage:

Apr 19 2018

BRIEF-Joseph Payne Says Calling On Arcturus Therapeutics' Board To Hold EGM "Without Further Delay"

* JOSEPH PAYNE SAYS CALLING ON ARCTURUS THERAPEUTICS' BOARD TO HOLD ITS EXTRAORDINARY GENERAL MEETING "WITHOUT FURTHER DELAY"

Apr 13 2018

BRIEF-‍Arcturus Therapeutics Initiates Lawsuit Against Former CEO Joseph Payne

* ‍ARCTURUS THERAPEUTICS INITIATES LAWSUIT AGAINST FORMER PRESIDENT AND CEO JOSEPH PAYNE

Mar 27 2018

BRIEF-Arcturus Therapeutics issues statement on extraordinary general meeting of shareholders

* ARCTURUS THERAPEUTICS - ‍CO SOUGHT TO APPOINT NEW INDEPENDENT AUDITOR IN ORDER TO REPORT FINANCIAL RESULTS, INCLUDING ITS FINANCIAL STATEMENTS FOR 2017​

Feb 26 2018

BRIEF-Arcturus Therapeutics Comments On Amended 13D Filing

* ARCTURUS THERAPEUTICS LTD - COMMENTED ON AMENDED 13D FILING BY JOSEPH E. PAYNE

Feb 16 2018

BRIEF-Joseph Payne Reports 13.7 Pct Stake In Arcturus Therapeutics

* JOSEPH PAYNE SAYS EMAILED LETTER DATED FEBRUARY 12, REQUESTED BOARD OF ARCTURUS THERAPEUTICS CONVENE EXTRAORDINARY GENERAL MEETING AS SOON AS POSSIBLE

Feb 13 2018

BRIEF-Certain Arcturus Therapeutics Shareholders Expressed Support For Former CEO Joseph Payne's Leadership

* FORMER CEO JOSEPH PAYNE SAYS HE WAS APPROACHED BY CERTAIN ARCTURUS THERAPEUTICS SHAREHOLDERS, WHO EXPRESSED SUPPORT FOR HIS CONTINUED LEADERSHIP

Feb 06 2018

Earnings vs. Estimates